TraceLink unveils Automated Validation Manager
Removes burden of validating software updates for Life Sciences Cloud customers.
TraceLink has launched Automated Validation Manager (AVM) – a revolutionary web-based offering that automates the entire validation lifecycle of the TraceLink Life Sciences Cloud on an ongoing basis.
Customers using the Life Sciences Cloud already benefit from the only network-tenant solution that enables them to quickly adapt to rapid change in today’s continuously evolving regulatory environment. By subscribing to TraceLink AVM, customers no longer have to deploy manual, labor-intensive, paper-based validation procedures and instead are assured that their current instance of the Life Sciences Cloud is automatically validated to meet GxP compliance requirements in accordance with industry standards, such as GAMP 5. Using nothing more than a browser, TraceLink AVM customers simply login to a web portal and review any aspect of the validation lifecycle, including the validation plan, traceability matrix, test results and final validation certificates. Once validation is complete, TraceLink AVM customers will know that all required IQ, OQ, and PQ test scripts have been successfully executed in a dedicated validation environment.
“We introduced our network-tenant Life Sciences Cloud platform in 2009 as a revolutionary architecture that would enable life sciences companies in any geographic market to eliminate the risks associated with frequent technology updates resulting from continuously changing laws, data exchange requirements and trade partner demands,” said Shabbir Dahod, president and CEO of TraceLink. “Automated Validation Manager is the next step in managing the complexity of computer systems validation for our customers, ensuring that they have an easy-to-use solution that removes the business and operational burdens of manual validation and keeps them continuously compliant.”
TraceLink Automated Validation Manager: How It Works
As regulatory demands evolve and changes occur, life sciences companies must be able to quickly adapt their track and trace solutions in order to maintain continuous compliance and prevent disruption to product flow. Technology solutions must also evolve to keep pace with these industry changes, and life sciences companies need to validate software updates to mitigate operational risk by confirming that all new software functionality is working as intended. With the unpredictability associated with pharmaceutical supply chain compliance, companies face the challenge of managing and validating software updates more frequently – often resulting in the need for specific staff expertise and repeated labor intensive testing. Those who outsource validation because they do not have in-house expertise face high costs for consultants to manage the entire validation process for them.
TraceLink AVM removes both the in-house and outsourcing burdens of validation by automating validation testing and confirming that current TraceLink software capabilities perform as intended. The end result is a fully executed, 100% paperless package compliant with GxP compliance standards, such as GAMP 5. Every TraceLink AVM customer will benefit from
TraceLink AVM is expected to be available by the third quarter of 2017 for TraceLink customers.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance